Sentry Investment Management LLC Sells 47 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Sentry Investment Management LLC cut its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXXFree Report) by 9.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 435 shares of the company’s stock after selling 47 shares during the quarter. Sentry Investment Management LLC’s holdings in IDEXX Laboratories were worth $241,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the company. Patron Partners LLC boosted its position in IDEXX Laboratories by 2.7% during the fourth quarter. Patron Partners LLC now owns 765 shares of the company’s stock valued at $425,000 after purchasing an additional 20 shares during the last quarter. NewEdge Wealth LLC boosted its position in IDEXX Laboratories by 3.1% during the fourth quarter. NewEdge Wealth LLC now owns 659 shares of the company’s stock valued at $366,000 after purchasing an additional 20 shares during the last quarter. Phoenix Holdings Ltd. lifted its position in shares of IDEXX Laboratories by 2.8% in the third quarter. Phoenix Holdings Ltd. now owns 769 shares of the company’s stock valued at $338,000 after buying an additional 21 shares during the last quarter. BluePath Capital Management LLC lifted its position in shares of IDEXX Laboratories by 1.8% in the fourth quarter. BluePath Capital Management LLC now owns 1,197 shares of the company’s stock valued at $663,000 after buying an additional 21 shares during the last quarter. Finally, Harbour Investments Inc. lifted its position in shares of IDEXX Laboratories by 24.1% in the fourth quarter. Harbour Investments Inc. now owns 108 shares of the company’s stock valued at $44,000 after buying an additional 21 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on IDXX. The Goldman Sachs Group raised their price objective on IDEXX Laboratories from $500.00 to $650.00 and gave the company a “buy” rating in a research report on Wednesday, January 17th. Barclays raised their price objective on IDEXX Laboratories from $605.00 to $655.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. William Blair reaffirmed an “outperform” rating on shares of IDEXX Laboratories in a research report on Tuesday, April 9th. Piper Sandler cut IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 price objective for the company. in a research report on Tuesday, January 30th. Finally, StockNews.com raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Wednesday, December 20th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $591.50.

Check Out Our Latest Stock Analysis on IDEXX Laboratories

Insider Activity

In other news, CFO Brian P. Mckeon sold 23,326 shares of IDEXX Laboratories stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $570.01, for a total value of $13,296,053.26. Following the transaction, the chief financial officer now owns 29,718 shares in the company, valued at approximately $16,939,557.18. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, CFO Brian P. Mckeon sold 23,326 shares of IDEXX Laboratories stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $570.01, for a total value of $13,296,053.26. Following the transaction, the chief financial officer now owns 29,718 shares in the company, valued at approximately $16,939,557.18. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP George Fennell sold 8,198 shares of the business’s stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $573.87, for a total value of $4,704,586.26. Following the sale, the senior vice president now owns 6,712 shares in the company, valued at approximately $3,851,815.44. The disclosure for this sale can be found here. In the last quarter, insiders have sold 43,524 shares of company stock worth $24,871,960. Insiders own 2.18% of the company’s stock.

IDEXX Laboratories Price Performance

IDEXX Laboratories stock opened at $489.57 on Wednesday. The stock’s fifty day moving average price is $543.74 and its two-hundred day moving average price is $508.92. IDEXX Laboratories, Inc. has a one year low of $372.50 and a one year high of $583.39. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.57 and a quick ratio of 1.17. The firm has a market cap of $40.66 billion, a PE ratio of 48.62, a price-to-earnings-growth ratio of 3.78 and a beta of 1.26.

IDEXX Laboratories (NASDAQ:IDXXGet Free Report) last posted its quarterly earnings data on Monday, February 5th. The company reported $2.32 EPS for the quarter, topping analysts’ consensus estimates of $2.12 by $0.20. IDEXX Laboratories had a return on equity of 71.66% and a net margin of 23.08%. The firm had revenue of $901.60 million for the quarter, compared to analyst estimates of $891.88 million. During the same quarter last year, the company earned $2.05 EPS. The company’s revenue was up 8.8% on a year-over-year basis. As a group, research analysts expect that IDEXX Laboratories, Inc. will post 11.15 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

(Free Report)

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

See Also

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.